Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study-Reference-Cited by-同舟云学术

Feasibility of Testing Client Preferences for Accessing Injectable Opioid Agonist Treatment (iOAT): A Pilot Study

Published:2022-12 Issue: Volume:Volume 16 Page:3405-3413
ISSN:1177-889X
Container-title:Patient Preference and Adherence
language:en
Short-container-title:PPA

Author:

Dobischok Sophia^ORCID,Metcalfe Rebecca K,Matzinger Elizabeth Angela,Lock Kurt,Harrison Scott,MacDonald Scott,Amara Sherif,Schechter Martin T,Bansback Nick,Oviedo-Joekes Eugenia

Publisher

Informa UK Limited

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Social Sciences (miscellaneous),Medicine (miscellaneous)

Reference48 articles.

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th. American Psychiatric Publishing; 2013.

2. The societal cost of heroin use disorder in the United States

3. The global burden of disease attributable to alcohol and drug use in 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

4. The State of Opioid Agonist Therapy in Canada 20 Years after Federal Oversight

5. Illicit Drug Toxicity Deaths in BC: January 1, 2012 – June 30, 2022; 2022.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Client preferences for the design and delivery of injectable opioid agonist treatment services: Results from a best–worst scaling task;Addiction;2024-07-25

2. “I'm just searching to get better”: Constructions of treatment citizenship on injectable opioid agonist treatment;Social Science & Medicine;2024-05

3. Clients’ experiences on North America’s first take-home injectable opioid agonist treatment (iOAT) program: a qualitative study;BMC Health Services Research;2023-05-26

4. How injectable opioid agonist treatment (iOAT) care could be improved? service providers and stakeholders’ perspectives;Drugs: Education, Prevention and Policy;2023-02-07

5. Measuring the preferences of injectable opioid agonist treatment (iOAT) clients: Development of a person-centered scale (best-worst scaling);International Journal of Drug Policy;2023-02